StemoniX® Opens New, State-of-the-Art Research & Development Facility Facility to lead discovery of new preclinical applications, disease modeling techniques, and drug discovery opportunities utilizing StemoniX’s proprietary microOrgan® platforms

StemoniX® Opens New, State-of-the-Art Research & Development Facility Facility to lead discovery of new preclinical applications, disease modeling techniques, and drug discovery opportunities utilizing StemoniX’s proprietary microOrgan® platforms

Back to Latest News StemoniX® Opens New, State-of-the-Art Research & Development Facility Facility to lead discovery of new preclinical applications, disease modeling techniques, and drug discovery opportunities utilizing StemoniX’s proprietary microOrgan® platforms   La Jolla, CA, July 8, 2019 – StemoniX® a biotech company revolutionizing how new medicines are discovered, announced today the opening of its new, state-of-the-art [...]
StemoniX’s microBrain® 3D to be Featured in Podium Presentation at World Pharma Week’s 18ᵗʰ Annual World Preclinical Congress StemoniX's Director, Research and Development, Fabian Zanella, PhD, to present during the "iPS Cells for CNS Drug Discovery and Development" session

StemoniX’s microBrain® 3D to be Featured in Podium Presentation at World Pharma Week’s 18ᵗʰ Annual World Preclinical Congress StemoniX's Director, Research and Development, Fabian Zanella, PhD, to present during the "iPS Cells for CNS Drug Discovery and Development" session

Back to Latest News StemoniX® Uses microBrain® 3D to be Featured in Podium Presentation at World Pharma Week's 18ᵗʰ Annual World Preclinical Congress StemoniX's Director, Research and Development, Fabian Zanella, PhD, to present during the "iPS Cells for CNS Drug Discovery and Development" session   MAPLE GROVE, MN, June 11, 2019 – StemoniX® Inc., a biotech [...]
StemoniX CEO Ping Yeh sat down with Moe Alsumidaie at Applied Clinical Trials to discuss the future of drug discovery!

StemoniX CEO Ping Yeh sat down with Moe Alsumidaie at Applied Clinical Trials to discuss the future of drug discovery!

StemoniX CEO Ping Yeh sat down with Moe Alsumidaie at Applied Clinical Trials to discuss the future of drug discovery! May 20, 2019 – The Future of Clinical Development is Here: Research in MicroOrgans. The concept of running preclinical models and clinical trials in a petri dish was the talk of futurists and speculators several [...]
StemoniX Announces Collaborative Research Agreement with the NIH’s National Center for Advancing Translational Sciences (NCATS)

StemoniX Announces Collaborative Research Agreement with the NIH’s National Center for Advancing Translational Sciences (NCATS)

StemoniX® Announces Collaborative Research Agreement with the NIH’s National Center for Advancing Translational Sciences (NCATS) StemoniX and NCATS to explore the use of microBrain® 3D in advancing new treatments for pain, opioid misuse and addiction as part of the NIH HEAL Initiative MAPLE GROVE, MN, MAY 1, 2019 – StemoniX® Inc., a biotech company revolutionizing [...]
Axios Newsletter

Axios Newsletter

Axios: StemoniX Lands $14.4M to Continue Development of ‘Micro-Organs’ March 1, 2019 – StemoniX Inc, a Minnesota-based biotech company, has secured $14.4 million in Series B funding led by Brightstone Venture Capital, with Crescent Ridge Partners, SEED San Diego, Alumni Ventures Group, Keshif Ventures and Mayo Clinic also participating. Read more here
FierceBiotech

FierceBiotech

StemoniX rakes in $14.4M for micro-organ drug testing chips built from stem cells’ February 28, 2019 – Microtissue developer StemoniX has secured $14.4 million in funding to commercialize its organ-on-a-chip platforms for drug development. Read more here
MinneInno Article

MinneInno Article

MinneInno: StemoniX Lands $14.4M to Continue Development of ‘Micro-Organs’ February 28, 2019  – StemoniX, a biotech startup using stem cells to create micro-organs for drug testing and development, has raised $14.4 million in a fresh round of funding, the company announced Thursday. Read more here
The PE Hub Network

The PE Hub Network

The PE Hub Network: Biotech company StemoniX nets $14.4 mln Series B February 28, 2019 – Minnesota-based StemoniX Inc, a biotech company, has secured $14.4 million in Series B funding. Brightstone Venture Capital led the round with participation from other investors that included Crescent Ridge Partners, SEED San Diego, Alumni Ventures Group, Keshif Ventures and Mayo Clinic. Read more here
WSJ Venture Capital

WSJ Venture Capital

WSJ Venture Capital: Term Sheet Friday March 1, 2019 – StemoniX Inc, a Minnesota-based biotech company, raised $14.4 million in Series B funding. Brightstone Venture Capital led the round, and was joined by investors including Crescent Ridge Partners, SEED San Diego, Alumni Ventures Group, Keshif Ventures and Mayo Clinic. Read more here
StemoniX® Secures $14.4 Million to Accelerate Commercialization of microOrgan® Drug Discovery Platforms

StemoniX® Secures $14.4 Million to Accelerate Commercialization of microOrgan® Drug Discovery Platforms

Back to Latest News StemoniX® Secures $14.4 Million to Accelerate Commercialization of microOrgan® Drug Discovery Platforms Series B financing will drive expansion of commercial operations and development of new microOrgan® platforms MAPLE GROVE, MN, FEBRUARY 28, 2019 – StemoniX® Inc., a biotech company revolutionizing how new medicines are discovered, announced today that it has secured [...]